Major outcome trials—including LEADER and SUSTAIN-6—have shown that GLP-1 RAs slow the progression of albuminuria and improve composite kidney end points in individuals with T2D [194,195], while concomitantly promoting weight loss and superior glycemic control, which further protects renal function. Here, GLP1R is linked to type 2 diabetes mellitus.